Dr. Leslie on the Methods of the ZUMA-7 Trial in Relapsed/Refractory LBCL

Video

In Partnership With:

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discusses the methods utilized in the phase 3 ZUMA‑7 trial (NCT03391466) in relapsed/refractory large B-cell lymphoma (LBCL).

The study randomized patients 1:1 to receive either the CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta), or platinum-based salvage chemotherapy followed by autologous stem cell transplantation (ASCT), Leslie says.

Notably, 94% of patients randomized to the CAR-T arm were administered axi-cel, compared with 36% of patients in the standard-of-care arm who received an ASCT, Leslie explains. High-risk patients tend to become chemorefractory, underscoring the need to get more patients to ASCT under the current standard of care, Leslie concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,